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Abstract
Background: Optimal cytoreduction (macroscopic Residual Tumor, RT = 0) is the best survival predictor factor in
epithelial ovarian cancer (EOC). It doesn’t exist a consolidated criteria to predict optimal surgical resection at interval
debulking surgery (IDS). The aim of this study is to develop a predictive model of complete cytoreduction at IDS.
Methods: We, retrospectively, analyzed 93 out of 432 patients, with advanced EOC, underwent neoadjuvant
chemotherapy (NACT) and IDS from January 2010 to December 2016 in two referral cancer centers. The correlation
between clinical-pathological variables and residual disease at IDS has been investigated with univariate and
multivariate analysis. A predictive score of cytoreduction (PSC) has been created by combining all significant
variables. The performance of each single variable and PSC has been reported and the correlation of all significant
variables with progression free survival (PFS) has been assessed.
Results: At IDS, 65 patients (69,8%) had complete cytoreduction with no residual disease (R = 0). Three criteria
independently predicted R > 0: age ≥ 60 years (p = 0.014), CA-125 before NACT > 550 UI/dl (p = 0.044), and
Peritoneal Cancer Index (PCI) > 16 (p < 0.001). A PSC ≥ 3 has been associated with a better accuracy (85,8%), limiting
the number of incomplete surgeries to 16,5%. Moreover, a PCI > 16, a PSC ≥ 3 and the presence of R > 0 after IDS
were all significantly associated with shorter PFS (p < 0.001, p < 0.001 and p = 0.004 respectively).
Conclusions: Our PSC predicts, in a large number of patients, complete cytoreduction at IDS, limiting the rate of
futile extensive surgeries in case of presence of residual tumor (R > 0). The PSC should be prospectively validated in
a larger series of EOC patients undergoing NACT-IDS.
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Background
Ovarian cancer is the leading cause of death from
gynecological malignancies. In 2017, 22,400 new cases are
expected in the United States. Currently, more than 75%
of women with ovarian cancer have advanced disease
[International Federation of Gynecology and Obstetrics
(FIGO) stage IIIC or IV] at diagnosis and their 5-years
survival rate is less than 30% [1].
Primary debulking surgery (PDS) followed by
platinum-based chemotherapy has long been consid-
ered the only standard treatment for advanced epithe-
lial ovarian cancer (EOC) [2]. This approach validity
has been supported by several retrospective studies
consistently demonstrating that upfront optimal cytor-
eduction (residual tumor nodules ≤1 cm or R ≤ 1) is
associated with longer survival [3, 4]. Unfortunately, PDS
is not always associated with optimal cytoreduction and
can be complicated by severe perioperative morbidity [5,
6]. More recently, neoadjuvant chemotherapy (NACT)
with delayed surgery (interval debulking surgery, IDS) is
increasingly adopted in patients with advanced EOC [7].
This tendency is sustained by the results of two random-
ized phase III trials, showing that NACT-IDS improves
optimal debulking rates and reduces surgery-related
complications with no detrimental effect on survival, in
comparison with PDS, at least in patients with high tumor
load [8, 9]. However both trials have been criticized for
the poor performances of PDS arm [10, 11].
However, a significant proportion of patients cannot
be optimally cytoreduced even after NACT-IDS and this
leads to the morbidity of surgery with no expected sur-
vival benefit [12–14]. Although it is common practice to
attempt IDS only in patients responding to NACT, this
approach causes several unnecessary laparotomies, if
optimal cytoreduction cannot be achieved, and in other
cases they are not applied also if the conditions are
appropriate. Single variables have been combined into
predictive cytoreduction models to improve accuracy in
the settings of PDS [15] and recurrent disease [16, 17].
Unfortunately, predictive models have not been developed
for patients undergoing IDS.
Therefore, the aim of this study is to develop a pre-
dictive model of surgical outcome at IDS, to improve the
selection of patients that can benefit of a maximal surgi-
cal effort.
Methods
Study population
A total of 432 patients with histologically confirmed
diagnosis EOC have been operated between January 1st,
2010, and December 31st, 2016 at Candiolo Cancer
Institute-IRCCS and Sant’Anna Hospital, two high-volume
gynecological cancer centers in the North-West of Italy.
All patients had preoperative computed tomography (CT)
of the chest, abdomen and pelvis with intravenous
contrast and serum Ca-125 assessment. In all cases, a
multidisciplinary board, including a gynecologist and/or
a surgeon, a medical oncologist and a radiologist with
specific training and expertise in ovarian cancer evalu-
ated the feasibility of surgical resection. The patients
underwent PDS when optimal cytoreduction has been
deemed achievable, while NACT - IDS was the pre-
ferred option when the extent/localization of the dis-
ease would likely preclude optimal cytoreduction and/
or the patient would not tolerate extensive surgery due
to age or co-morbidities. All 93 patients who under-
went both NACT and IDS were included in the present
study. The following variables has been prospectively
entered into a database and retrospectively analyzed:
age, performance status (PS) according to Eastern
Cooperative Oncology Group (ECOG), comorbidities
according to the Chronic Disease Score (CDS) [18], FIGO
stage, grade and histology, serum CA-125 at diagnosis
before surgery and after IDS [19], type of chemotherapy,
peritoneal cancer index (PCI) according to Sugarbaker
[20] at IDS assessed during laparoscopy, residual disease
(R) after IDS, date of radiological progression (PD) after
chemotherapy or last follow-up.
All patients signed a written informed consent and the
institutional review board of our Institutions provided
their approval.
Statistical analysis
We performed univariate and multivariate logistic re-
gression analysis, Fisher exact test and chi-square test
to search patients’ and tumors’ characteristics that were
predictive of complete cytoreduction. Receiver Operat-
ing Curve (ROC) analysis has been also adopted to as-
sess the best cut-off values to predict the likelihood of
incomplete cytoreduction at IDS of continuous vari-
ables. We used all significant variables at multivariate
analysis to create a predictive score of cytoreduction
(PSC). We assigned one or two points to each criterion,
according to accuracy (1 point if < 75%, 2 points if
≥75%). We estimated progression-free survival (PFS)
with the Kaplan-Meier method and we compared it
using the log-rank test. We considered p < 0.05 statisti-
cally significant. We performed all analyses using the
SPSS statistical software program, version 22.0 (IBM
SPSS Inc., Chicago, IL, United States of America).
Results
Ninety-three patients with predominantly advanced stage
(FIGO IIIC-IV: 75,3%), serous high grade (87%) EOC
undergoing NACT and IDS were enrolled. At the time
of diagnosis, median CA-125 was 2121 UI/dL (range
28–10,454 UI/dL) and Chronic Disease Score (CDS)
was ≥2 in 34,4% of the patients. Carboplatin plus
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paclitaxel was the most utilized chemotherapeutic
regimen (87,3%), with only three patients receiving
carboplatin single-agent and two patients receiving
carboplatin plus pegylated lyposomal doxorubicin, due to
hypersensitivity to paclitaxel. Sixty-five patients (69,8%)
had complete cytoreduction at IDS. For continuous vari-
ables, ROC analysis identified age ≥ 60 years, CA-125
levels before NACT > 550 UI/dL, CA-125 levels after
NACT > 33 UI/dL, CA-125 reduction after NACT < 96%
and PCI > 16 as optimal cut-offs to predict the surgical
outcome. All the above mentioned variables were sig-
nificantly correlated with incomplete cytoreduction at
univariate analysis. However, at multivariate analysis,
only age (p = 0.007), CA-125 before NACT (p = 0.014)
Table 1 Univariate and multivariate analysis of variables associated with incomplete cytoreduction at interval debulking surgery
Total (93Pts.) R0 (65Pts.) Non-R0 (28 Pts.) Uni-variate p value Multi-variate p value
Age, years
Median (range) 60 (36–82) 59,5 (36–82) 65,7 (47–82) NS
Age≥ 60 54 (58%) 32 (49,2%) 22 (78,6%) 0.011 0.007
FIGO stage
IIIA 9 (9,7%) 6 (9,2%) 3 (10,7%)
IIIB 14 (15%) 9 (13,8%) 5 (17,9%) NS
IIIC 58 (62,4%) 43 (66,2%) 15 (53,5%)
IV 12 (12,9%) 7 (10,8%) 5 (17,9%)
Histology
High-grade serous 81(87%) 57 (87,6%) 24 (85,7%)
Endometroid 4 (4,3%) 2 (3,1%) 2(7,1%) NS
Mucinous 2 (2,2%) 1 (1,5%) 1 (3,6%)
Clear cell 2 (2,2%) 2 (3,1%) 0
Other/non specified 4 (4,3%) 3 (4,6%) 1 (3,6%)
ECOG Performance Status
0 34 (37%) 26 (40%) 8 (29,6%) NS
1 44 (47,8%) 30 (46,2%) 14 (51,9%)
2 15 (15,2%) 9 (13,8%) 6 (21,4%)
Ca 125 values, UI/dl
Median CA-125 at diagnosis (range) 2121 (10454–28) 1964 2793 NS NS
CA-125 at diagnosis > 550 71 (76,3%) 46 (70,8%) 25 (89,3%) 0.044 0.014
Median CA-125 post NACT (range) 342 (2620–7) 163 598 0.055 NS
Ca 125 post NACT > 33 60 (65,9%) 35 (55,6%) 25 (89,3%) 0.002 NS
CA 125 reduction post NACT < 96% 34 (38,2%) 26 (41,9%) 8 (29,6%) 0.034 NS
Chronic Disease Score (CDS)
1 61 (65,6%) 44 (67,7%) 17 (60,7%)
2 24 (25,8%) 17 (26,2%) 7 (25%) NS
3 8 (8,6%) 4 (6,2%) 4 (14,3%)
Peritoneal Cancer Index
0–16 68 (73,1%) 58 (85,3%) 10 (35,8%) < 0.001 < 0.001
> 16 25 (26,9%) 7 (10,7%) 18 (64,2%)
Chemotherapy regimen
- Carboplatin plus paclitaxel 81 (87,3%) 57 (87,6%) 24 (85,7%) NS
- Single agent carboplatin 3 (3,2%) 2 (3,1%) 1 (3,6%)
- Carboplatin plus PLD 2(2,2%) 2 (3,1%) 0
- Carboplatin plus paclitaxel plus bevacizumab 7 (7,6%) 4 (6,2%) 3 (10,7%)
Pts patients, R0 complete cytoreduction, FIGO International Federation of Gynaecology and Obstretics, ECOG Eastern Cooperative Oncology Group, NACT
neoadjuvant chemotherapy, PLD pegylated liposomal doxorubicin, NS not significant
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and PCI (p < 0.001) maintained the statistical signifi-
cance. For complete baseline patients’ characteristics
and statistical correlations see Table 1.
PCI was the best predictor of surgical outcome, with
accuracy more than 80% (Table 2). Therefore, we mod-
eled a predictive score of incomplete cytoreduction
(PSC) by assigning a value of 1 point to age and CA-125
at diagnosis and 2 points to PCI according to accuracy.
If applied, a PSC ≥3 could have selected all patients
for whom complete cytoreduction was not achievable
(100%) by limiting at 16,5% the rate of surgical attempts
leading to a R > 1 cm (Table 3).
After a mean follow up of 27 months (range
19.6–34.6 months), 39 patients showed disease pro-
gression. Among the variables considered, a PCI > 16
at IDS (p < 0.001), a PSC ≥3 (p < 0.001) and the pres-
ence of residual disease after IDS (p = 0.004) were all
significantly associated with shorter PFS (Fig. 1).
Discussion
A key issue in patients with advanced EOC is the selec-
tion of patients suitable for complete surgical cytoreduc-
tion. Predictive models of surgical outcome based on
computed tomography alone [15], or integrated by
serum CA-125 levels [21, 22], patient age and perform-
ance status [23] have been developed to assist physicians
in the decision between PDS or NACT – IDS. Laparo-
scopic scores have also been proposed [24], with a recent
randomized study demonstrating that triage laparoscopy
could limit the rate of laparotomies leading to incom-
plete cytoreduction (“futile laparotomies”) at 10% [25].
If the choice between PDS and NACT-IDS is complex
[7], even more controversial is the optimal clinical
management of women who undergo NACT according
to the indication, timing and extent of IDS based on
their stage, comorbidities and, most of all, clinical
response [26]. As recently reported, there is still an ab-
sence of selecting criteria for patients suitable for
NACT/IDS underlining that this approach is still object
of debate [27].
Resection of all visible disease should always be the
goal in advanced EOC, but it may be particularly im-
portant after NACT when patients face their last best
chance to receive an effective surgery. Furthermore, se-
lection is crucial, since patients who can be cytoreduced
to no macroscopic residual disease may be the only once
gaining a survival benefit from surgery at IDS. This
opinion is sustained by the randomized study of Vergote
et al. where the hazard ratio (HR) of overall survival was
not significantly different for R = 0 at IDS (HR 1.11;
p = 0.561) or R ≤ 1 cm at PDS (HR 1.37; p = 0.130) as
compared to R = 0 at PDS (reference), but was signifi-
cantly worse for R ≤ 1 cm at IDS (HR 1.73; p = .0054)
[8]. The randomized phase III trial TRUST
(NCT02828618) is investigating the role of PDS versus
NACT+IDS in large volume comprehensive cancer cen-
ters and has already enrolled one third of 686 estimated
patients; final results are expected for 2019.
Computed tomography, serum markers and staging
laparoscopy have all been investigated for the prediction
of complete resection at IDS with variable results. Evalu-
ation of response to NACT by computed tomography is
challenging [28] and serum CA-125 variations [29–31]
or thresholds [32, 33] have limited accuracy. It has been
reported that a laparoscopic score could identify all pa-
tients likely to be optimally debulked at IDS, but with
the drawback of 32.6% futile laparotomies [34].
At our Institutions, patients with clinical/radiological
progressive disease during the first 3–4 courses of NACT,
either underwent diagnostic laparoscopy or withdrew
chemotherapy, were excluded from the current study. In
patients with radiological response/stable disease to
Table 2 Diagnostic performance and assigned score of significant variables of incomplete cytoreduction at interval debulking surgery
Variable Sens (%) Spec (%) NPV (%) PPV (%) Acc (%) Assigned scorea
Age > 60 years 78,6 50,7 84,6 40,7 59,1 1
CA-125 at diagnosis ≥550 UI/dl 89,2 29,2 86,3 35,2 47,3 1
PCI > 16 62,5 90,1 85,9 71,4 82,3 2
aTo develop a predictive score of cytoreduction (PSC) for each criterion 1 point was assigned if accuracy is < 75% and 2 points if > 75%. SE sensitivity, SP specificity, NPV
negative predictive value, PPV positive predictive value, Acc accuracy
Table 3 Diagnostic performance of significant variables of incomplete cytoreduction at interval debulking surgery
Variable NPV (%) Unnecessarily explored (1-NPV) (%) PPV (%) Inappropriately unexplored (1-PPV) (%)
Age > 60 years 84,6 15,4 40,7 59,1
CA-125 at diagnosis > 550 UI/dl 86,3 13.7 35,2 64,6
PCI > 16 85,9 14,1 71,4 28,6
PSC > 3 83,5 16,5 100 0
CA-125 Cancer Antigen 125, PCI Peritoneal Cancer Index, PSC Predictive score of cytoreduction, NPV negative predictive value, PPV positive predictive value, Acc
accuracy, Unnecessary explored (1-NPV): number of cases that would be considered as resectable disease but non-optimally cytoreduced at laparotomy;
Inappropriately unexplored (1-PPV): number of cases that would be considered as unresectable but optimally cytoreduced after laparotomy
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NACT we rely on laparotomy to define if radical sur-
gery is appropriate or not. In fact, direct visualization
and palpation of the whole abdominal cavity is essential
for accurate PCI estimation, which is in turn correlated
with tumor resectability and prognosis [20, 35]. Al-
though we acknowledge that the role of PCI in ovarian
cancer is under discussion [36, 37] due to its assess-
ment, its low reproducibility and limited utilization, in
our series PCI outperformed all other significant
predictors and a cut-off < 16 was able to identify almost
90% of patients who could be completely debulked.
Nevertheless, this high PPV was obtained with the
drawback of 28,6% of unexplored laparotomies. There-
fore, we assessed whether other information could add
predictive value to PCI by modeling a PSC. Four signifi-
cant variables reflecting patient (age) and tumor char-
acteristics (PCI and preoperative Ca 125), as well as
response to NACT (CA 125 decrease) has been used.
Our results indicate that, with a cut a cut-off set at > 4,
our PSC may allow to identify all patients who cannot
be completely cytoreduced at the price of 15% of futile
laparotomies.
In our series, R = 0 after IDS was the only parameter
significantly associated with PFS. Conversely, in a recent
retrospective series from the Mayo Clinic, older age (HR
1.60 per 10-years increase in age) and elevated CA-125
before IDS (HR 2.30 for CA-125 > 35 U/mL) were nega-
tively correlated with OS, while residual disease after
IDS did not reach statistical significance (median OS 1.9
vs. 2.6 years; P = 0.08) [38]. Indeed, some studies suggest
that the degree of pathological response to chemother-
apy could be more closely correlated to OS than the ab-
sence of residual tumor at IDS [39–42]. Although only
R = 0 reached statistical significance, the limited number
of events of our study may have hindered associations
between PFS and other variables, such as age and CA
125 decrease after NACT.
Conclusions
In conclusion, we showed that our PSC might help
surgeons to give a surgical chance to all patients that
could be completely debulked, therefore limiting the num-
ber of suboptimal surgeries at 16.5%. Both patient’s and
tumor’s characteristics likely concur to determine the
chance of complete debulking at IDS. Although the influ-
ence of tumor chemosensitivity on survival may supersede
the once of surgery, the selection of those patients who
can be cytoreduced to R = 0 after NACT is crucial to de-
rive the best trade-off from the benefits and the risks of an
extensive surgical effort. Our preliminary results suggest
that IDS after NACT should be performed in patients with
a PSC up to 2, while the value of surgery in patients scor-
ing 4 is likely minimal. In our analysis, we provide a two
high-volume-centers experience with standardized multi-
disciplinary care of EOC. The extrapolation equivalence of
PDS and NACT-IDS from the results of randomized stud-
ies [8, 9], has been questioned due to patients selection
and their poor surgical quality, which led to low both
cytoreduction and survival rates [43]. At IDS we obtained
a 69% complete cytoreduction rate by performing opera-
tions characterized by high surgical complexity, that were
guided by the same objective and performed with the
same effort as PDS. A prospective validation of the PSC
has been already planned at our Institutions.
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